- Home
- ITIC vs KALV Comparison
ITIC vs KALV Comparison
Compare ITIC & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITIC | KALV |
|---|---|---|
| Founded | 1972 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.1M | 551.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ITIC | KALV |
|---|---|---|
| Price | $271.94 | $16.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 18.2K | ★ 1.3M |
| Earning Date | 02-13-2026 | 03-11-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | ★ 25.81 | N/A |
| EPS | ★ 19.00 | N/A |
| Revenue | ★ $273,864,000.00 | $1,426,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $204.16 |
| P/E Ratio | $13.95 | ★ N/A |
| Revenue Growth | ★ 13.63 | N/A |
| 52 Week Low | $190.20 | $8.74 |
| 52 Week High | $288.98 | $19.00 |
Technical Indicators
Market Signals| Indicator | ITIC | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 66.71 | 54.58 |
| Support Level | $249.28 | $15.22 |
| Resistance Level | $259.00 | $16.16 |
| Average True Range (ATR) | 7.34 | 0.84 |
| MACD | 2.01 | 0.02 |
| Stochastic Oscillator | 99.73 | 75.72 |
Price Performance
Historical ComparisonAbout ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.